CA3177329A1 - Protein s antibodies, methods of making and uses thereof - Google Patents

Protein s antibodies, methods of making and uses thereof Download PDF

Info

Publication number
CA3177329A1
CA3177329A1 CA3177329A CA3177329A CA3177329A1 CA 3177329 A1 CA3177329 A1 CA 3177329A1 CA 3177329 A CA3177329 A CA 3177329A CA 3177329 A CA3177329 A CA 3177329A CA 3177329 A1 CA3177329 A1 CA 3177329A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177329A
Other languages
English (en)
French (fr)
Inventor
Sandip PANICKER
Adam David ROSENTHAL
Tony SangYoung BYUN
Quehuong Thi DONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vega Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3177329A1 publication Critical patent/CA3177329A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3177329A 2020-05-05 2021-05-05 Protein s antibodies, methods of making and uses thereof Pending CA3177329A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063020505P 2020-05-05 2020-05-05
US63/020,505 2020-05-05
US202163169755P 2021-04-01 2021-04-01
US63/169,755 2021-04-01
PCT/US2021/030900 WO2021226243A1 (en) 2020-05-05 2021-05-05 Protein s antibodies, methods of making and uses thereof

Publications (1)

Publication Number Publication Date
CA3177329A1 true CA3177329A1 (en) 2021-11-11

Family

ID=76076555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177329A Pending CA3177329A1 (en) 2020-05-05 2021-05-05 Protein s antibodies, methods of making and uses thereof

Country Status (11)

Country Link
US (4) US12441810B2 (enExample)
EP (1) EP4146705A1 (enExample)
JP (1) JP2023524807A (enExample)
KR (1) KR20230019097A (enExample)
CN (1) CN115916835A (enExample)
AU (1) AU2021268943A1 (enExample)
CA (1) CA3177329A1 (enExample)
GB (1) GB2610720A (enExample)
IL (1) IL297947A (enExample)
TW (2) TWI910161B (enExample)
WO (2) WO2021226245A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441810B2 (en) 2020-05-05 2025-10-14 Vega Therapeutics, Inc. Protein S antibodies, methods of making and uses thereof
GB202402535D0 (en) * 2024-02-22 2024-04-10 Imperial College Innovations Ltd Fusion proteins
WO2025240928A1 (en) * 2024-05-16 2025-11-20 Vega Therapeutics, Inc. Treatment of von willebrand disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187067A (en) 1986-12-15 1993-02-16 Teijin Limited Immunological determination of free human protein S and C4bp-protein S complex
US5366861A (en) 1987-08-12 1994-11-22 Teijin Limited Immunoassay and reagent kit used therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US6423313B1 (en) 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5321123A (en) 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
ES2142317T3 (es) * 1991-07-02 2000-04-16 Scripps Research Inst Polipeptidos de proteinas s y uso de los mismos.
DK0658168T3 (da) 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
US20030143759A1 (en) 1995-10-20 2003-07-31 Bjorn Dahlback Assays for determining anticoagulant cofactor activity
SE9604378D0 (sv) * 1996-11-27 1996-11-27 Tac Ab Methods and reagents for determining protein S
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20030124118A1 (en) 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US20080057059A1 (en) 2001-11-09 2008-03-06 Novo Nordisk Healthcare A/G Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
WO2007008966A1 (en) 2005-07-12 2007-01-18 The Scripps Research Institute Elisa to detect multimeric forms of a protein
EP1920068A4 (en) 2005-07-28 2008-08-13 American Diagnostica Inc LUPIC ANTICOAGULANT TEST
EP1919499A2 (en) 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
CN105705517A (zh) * 2013-11-07 2016-06-22 诺和诺德股份有限公司 用于治疗凝血障碍的新方法和抗体
CN106232615B (zh) * 2014-02-28 2021-06-01 3B制药有限公司 肽及其使用方法
US12441810B2 (en) 2020-05-05 2025-10-14 Vega Therapeutics, Inc. Protein S antibodies, methods of making and uses thereof
CN115884986A (zh) 2020-06-29 2023-03-31 Inserm(法国国家健康医学研究院) 抗蛋白s单域抗体和包含其的多肽
WO2024124136A1 (en) 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Also Published As

Publication number Publication date
US20230083243A1 (en) 2023-03-16
US20240425613A1 (en) 2024-12-26
CN115916835A (zh) 2023-04-04
AU2021268943A1 (en) 2022-11-24
EP4146705A1 (en) 2023-03-15
GB2610720A (en) 2023-03-15
WO2021226243A1 (en) 2021-11-11
US20230174672A1 (en) 2023-06-08
TW202208444A (zh) 2022-03-01
US12441810B2 (en) 2025-10-14
GB202217381D0 (en) 2023-01-04
US12145999B2 (en) 2024-11-19
TW202208443A (zh) 2022-03-01
TWI910161B (zh) 2026-01-01
US12421320B2 (en) 2025-09-23
US20240084038A1 (en) 2024-03-14
KR20230019097A (ko) 2023-02-07
IL297947A (en) 2023-01-01
JP2023524807A (ja) 2023-06-13
WO2021226245A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US12145999B2 (en) Protein S antibodies, methods of making and uses thereof
SG174344A1 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
US12304957B2 (en) Anti-CD161 antibodies and uses thereof
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
CN105705517A (zh) 用于治疗凝血障碍的新方法和抗体
AU2018214222C1 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
US20230227580A1 (en) Anti-vwf antibodies and uses thereof
TW201617371A (zh) 針對經活化之因子ｖ之抗體
WO2025166146A1 (en) Klk5/7 + ox40 targeting antibodies and uses thereof
AU2024232543A1 (en) Kallikrein antibodies and uses thereof
WO2025166138A1 (en) Klk5/7 + tslp targeting antibodies and uses thereof
RU2024106219A (ru) Антитела против ингибитора пути тканевого фактора и их применения
IL323198A (en) Dual inhibitory kallikrein antibodies and their uses
NZ756365B2 (en) Tissue factor pathway inhibitor antibodies and uses thereof
NZ756365A (en) Tissue factor pathway inhibitor antibodies and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250428

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250506

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250721

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250721

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260309

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421